Pharmaceutical leaders in the UK have responded positively to the outcome of the British general election on Friday, which returned Conservative Prime Minister Boris Johnson to power with a large majority.
The third national poll within just five years, the UK has struggled to overcome political deadlock caused by disagreements over the country’s impending departure from the European Union (EU).
That uncertainty had led pharmaceutical leaders in the country to caution against the prospect of a so-called “hard Brexit,” with many worrying that the supply of drugs into the UK could be disrupted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze